Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors

NCT ID: NCT01572467

Last Updated: 2016-07-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.

PURPOSE: This research trial is studying genes in tumor samples from younger patients with ovarian or testicular sex cord stromal tumors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* To assess the role of DICER1 mutations and miRNA pathways in the etiology and progression of ovarian or testicular sex cord stromal tumors.

OUTLINE: Archived tumor tissue samples are analyzed for D1CER1 mutation and mRNA expression by reverse-transcriptase polymerase chain reaction (RT-PCR) and laser micro dissector. Results are then correlated with medical data, including age at diagnosis, diagnosis, pathology report, presenting symptoms, family history, treatment, outcome, and length of follow-up, when available.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Childhood Germ Cell Tumor Leydig Cell Tumor Ovarian Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RNA analysis

Intervention Type GENETIC

gene expression analysis

Intervention Type GENETIC

mutation analysis

Intervention Type GENETIC

reverse transcriptase-polymerase chain reaction

Intervention Type GENETIC

laboratory biomarker analysis

Intervention Type OTHER

medical chart review

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Fixed and frozen tissue samples from the ATBR01 B1 tissue bank and from the International Pleuropulmonary Blastoma Registry, Children's Hospital of Boston, and Massachusetts General Hospital
* Tissue samples from patients diagnosed with:

* Ovarian

* Sertoli-Leydig cell tumor
* Juvenile granulosa cell tumor
* Adult granulosa cell tumor
* Gynandroblastoma
* Sex cord stromal tumor with annular tubules
* Sex cord stromal tumor, undifferentiated
* Sertoli tumor
* Leydig tumor
* Testicular:

* Granulosa cell tumor
* Sertoli tumor
* Leydig tumor
* Sertoli-Leydig
* Undifferentiated stromal tumor

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified
Maximum Eligible Age

120 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

Children's Oncology Group

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dana A. Hill, MD

Role: PRINCIPAL_INVESTIGATOR

Children's National Research Institute

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COG-ARAR12B2

Identifier Type: OTHER

Identifier Source: secondary_id

NCI-2012-00721

Identifier Type: REGISTRY

Identifier Source: secondary_id

ARAR12B2

Identifier Type: OTHER

Identifier Source: secondary_id

ARAR12B2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.